815 related articles for article (PubMed ID: 11714814)
1. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y
Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239
[TBL] [Abstract][Full Text] [Related]
3. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function.
Peng X; Hussain SF; Paterson Y
J Immunol; 2004 May; 172(10):6030-8. PubMed ID: 15128786
[TBL] [Abstract][Full Text] [Related]
4. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector.
Hussain SF; Paterson Y
J Immunother; 2004; 27(5):339-46. PubMed ID: 15314542
[TBL] [Abstract][Full Text] [Related]
6. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells.
Chen Z; Ozbun L; Chong N; Wallecha A; Berzofsky JA; Khleif SN
Cancer Immunol Res; 2014 Sep; 2(9):911-22. PubMed ID: 24872025
[TBL] [Abstract][Full Text] [Related]
7. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
8. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress.
Lin CW; Lee JY; Tsao YP; Shen CP; Lai HC; Chen SL
Int J Cancer; 2002 Dec; 102(6):629-37. PubMed ID: 12448006
[TBL] [Abstract][Full Text] [Related]
9. Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors.
Dominiecki ME; Beatty GL; Pan ZK; Neeson P; Paterson Y
Cancer Immunol Immunother; 2005 May; 54(5):477-88. PubMed ID: 15750832
[TBL] [Abstract][Full Text] [Related]
10. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
12. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.
Sewell DA; Douven D; Pan ZK; Rodriguez A; Paterson Y
Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):92-7. PubMed ID: 14732776
[TBL] [Abstract][Full Text] [Related]
13. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
Singh R; Dominiecki ME; Jaffee EM; Paterson Y
J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
[TBL] [Abstract][Full Text] [Related]
14. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene.
Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Rice CM; Ling M; Wu TC
J Immunol; 2001 May; 166(10):6218-26. PubMed ID: 11342644
[TBL] [Abstract][Full Text] [Related]
16. Listeriolysin O-deficient Listeria monocytogenes as a vaccine delivery vehicle: antigen-specific CD8 T cell priming and protective immunity.
Hamilton SE; Badovinac VP; Khanolkar A; Harty JT
J Immunol; 2006 Sep; 177(6):4012-20. PubMed ID: 16951364
[TBL] [Abstract][Full Text] [Related]
17. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.
Kim SH; Castro F; Paterson Y; Gravekamp C
Cancer Res; 2009 Jul; 69(14):5860-6. PubMed ID: 19584282
[TBL] [Abstract][Full Text] [Related]
18. Mucosal vaccine using CTL epitope-pulsed dendritic cell confers protection for intracellular pathogen.
Ozawa Y; Suda T; Nagata T; Hashimoto D; Nakamura Y; Enomoto N; Inui N; Koide Y; Nakamura H; Chida K
Am J Respir Cell Mol Biol; 2009 Oct; 41(4):440-8. PubMed ID: 19202004
[TBL] [Abstract][Full Text] [Related]
19. Listeriolysin O is a target of the immune response to Listeria monocytogenes.
Bouwer HG; Nelson CS; Gibbins BL; Portnoy DA; Hinrichs DJ
J Exp Med; 1992 Jun; 175(6):1467-71. PubMed ID: 1588276
[TBL] [Abstract][Full Text] [Related]
20. Genetic immunization of mice against Listeria monocytogenes using plasmid DNA encoding listeriolysin O.
Cornell KA; Bouwer HG; Hinrichs DJ; Barry RA
J Immunol; 1999 Jul; 163(1):322-9. PubMed ID: 10384131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
